Pharmacokinetics of once daily intra-peritoneal aztreonam and vancomycin in the treatment of CAPD peritonitis

Authors:

Abstract
The pharmacokinetics of aztreonam and vancomycin were studied in six adult patients who developed peritonitis during Continuous Ambulatory Peritoneal Dialysis. Aztreonam 3 g was added to the first exchange in each 24 h period with vancomycin 500 mg on the first day and 250 mg on each subsequent day (provided the pre-dose serum vancomycin concentration was < 10 mg/l) for a total of ten days. Aztreonam and vancomycin concentrations were measured in the serum and dialysate at 1, 2, 6, 12, 18 and 24 h after the initial dose and pre-dose on days 5 and 10. By the end of the ten day study all patients had recovered clinically and had a normal dialysate. For aztreonam, the mean peak serum concentration was 84·3 mg/l (range 59·6–102·8), the mean 24 h pre-dose serum concentration was 23·0 mg/l (range 8·6–39·2) and the mean 24 h pre-dose dialysate concentration was 15·5 mg/l (range 5·0–32·0). For vancomydn, the mean peak serum concentration was 10·2 mg/ (range 8·1–12·6), the mean 24 h pre-dose concentration was 5·5 mg/l (range 3·6–6·4), and the mean 24 h pre-dose dialysate concentration was 3·4 mg/l (range 2·4–4·6). In the treatment of CAPD peritonitis, once daily intra-peritoneal administration of aztreonam 3 g with vancomydn 500 mg initially and 250 mg on subsequent days (serum concentrations permitting) provides concentrations of antibiotic in both the serum and dialysate throughout the 24 h period in excess of the inhibitory concentrations of those organisms most frequently encountered in this condition.